Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3065293 | Journal of Neuroimmunology | 2008 | 4 Pages |
Abstract
In order to investigate the potential involvement of PTPN22 R620W in the pathogenesis of myasthenia gravis (MG), we performed a case–control study including 409 Swedish MG patients and 1557 normal controls. The W620 variant was significantly overrepresented in patients (odds ratio, 1.52; 95% confidence interval, 1.21–1.90; p = 0.00027). Incubation of patient (n = 100) derived PBMC cells with the autoantigen, the acetylcholine receptor, resulted in a significantly higher number of cells producing anti-AChR antibodies and IL-2 in W620 carriers, suggesting that PTPN22 W620 may be a loss-of-function variant in MG.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ann Kari Lefvert, Yaofeng Zhao, Ryan Ramanujam, Shuyang Yu, Ritva Pirskanen, Lennart Hammarström,